Overview

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

Status:
Active, not recruiting
Trial end date:
2024-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).
Phase:
Phase 3
Details
Lead Sponsor:
Alnylam Pharmaceuticals